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DNA hybridization arrays: a powerful technology for nutritional and
obesity research
Obesity is a serious and growing public health problem
throughout much of the world. In fact, obesity has reached
epidemic proportions in many developed countries.
Increased food intake and decreased energy expenditure
due to the sedentary lifestyle of our developed societies
have contributed to the widespread development of obesity.
However, these environmental factors cannot totally explain
the development of the disorder. In fact, genetic predis-
position for obesity may underlie the increased tendency for
weight gain in some individuals (Levin, 2000; Marti et al.
2000). Recent research has identified over 200 genes,
markers and chromosomal regions associated with or linked
to human obesity (Chagnon et al. 2000). The contribution of
genetic background to obese phenotypes is a complex
question yet to be answered. The major aim, therefore, is to
study those combinations of genes and mutations that are
implicated in the development of obesity in human subjects.
In order to be able to control the spread of obesity, it is
necessary to establish how environmental factors affect the
onset of obesity in individuals with a specific genetic
background.
With potentially thousands of genes examined in a single
hybridization, DNA hybridization array technology con-
stitutes a powerful tool to identify and compare patterns of
gene expression (Lander, 1999; Yang et al. 1999).
Thousands of DNA spots are robotically deposited on a
solid-state matrix (nylon membranes, glass microscope
slides, silicon or ceramic chips). These matrixes are then
hybridized with labelled cDNA representing total RNA
pools from test and reference samples. The differential
expression of genes between both test and reference samples
are detected based on the fact that the higher the expression
of a gene, the higher the intensity of the output labelled
signal (Schena et al. 1995, 1996; Duggan et al. 1999).
An array starts with the selection of the ‘probes’ to be
printed in the array. In many cases these probes are chosen
directly from databases like Genbank (Benson et al. 1998),
dbEST (Boguski et al. 1993) and UniGene (Schuler et al.
1996), the resource backbones of the array technologies
(Duggan et al. 1999). There are a variety of options for
making arrays (Bowtell, 1999; Cheung et al. 1999), with
four different array types developed according to the
different characteristics of the matrix, probe number and
density, array size and type of label. These include
macroarrays, microarrays, high-density oligonucleotide
arrays and microelectronic arrays (Freeman et al. 2000).
In the macroarrays the DNA probes are immobilized on a
membrane-based matrix, the targets are radioactively
labelled, and the different samples are hybridized on
individual separate arrays. Phosphoimagers are then used to
detect the amount of bound labelled target. Microarrays are
produced by spotting up to 10 000 polymerase chain
reaction products, or more, representing specific genes, onto
a glass or plastic slide matrix (Schena et al. 1995).
Following purification and quality control, a few nanolitres
of the polymerase chain reaction product are printed on
coated glass microscope slides using a computer-controlled
high-speed robot. Total RNA from both the test and
reference samples is labelled with fluorescent tags (for
example, red and green dye) by a single round of reverse
transcription. The matrix is then simultaneously hybridized
with the two resulting fluorescently-labelled cDNA in a
competitive manner, and fluorescence scanners are used for
detection (Schena et al. 1995, 1996; Fig. 1). The high-
density oligonucleotide arrays differ from the microarrays
in that the DNA probe is generated in situ on the surface of
the matrix by a method called photolitography. These arrays
(Genechipsw; Affymetrix, Santa Clara, CA, USA) can
contain between 40 000 and 60 000 probes, providing the
highest density of probes of any array. However, the probes
are limited in length and therefore specificity, and a
mismatch detection scheme has to be used to determine
specific hybridization (Lipshutz et al. 1999; Freeman et al.
2000). The microelectronic arrays, the newest hybridization
array, consist of sets of electrodes covered by a thin layer of
agarose coupled with an affinity moiety which provides
controlled electrophoretic fields (Cheng et al. 1998; Heller
et al. 2000).
Analysis and handling of the array data is one of the most
difficult aspects in the utilization of the technology. The
images of the scanner are imported into software which has
to transform the fluorescence data into information about the
clones, such as gene name, clone identifier, intensity values,
intensity ratios, normalization constant and CI (Duggan
et al. 1999). Clustering algorithms (hierarchical and non-
hierarchical) have been the most used tools for analysing
array data, and make it possible to find groups of genes or
clusters with similar behaviour (Brazma & Vilo, 2000; Celis
et al. 2000).
Due to the adaptable nature of the fabrication and
hybridization methods, these techniques have been widely
applied. Hybridization arrays have been applied to the
discovery of sets of genes that have roles in diseases such
as cancer (DeRisi et al. 1996; Kononen et al. 1998; Cole
et al. 1999; Marx, 2000; Sallinen et al. 2000), insulin
resistance (Aitman et al. 1999), hypertension (Lee et al.
2000), rheumatoid arthritis and inflammatory bowel
disease (Heller et al. 1997).
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cDNA biochips, therefore, constitute an extraordinary
tool for use by nutritionists (Trayhurn, 1998) and obesity
researchers to identify those combinations of genes (known
and unknown) that are implicated in the development of
obesity and other nutrition-related disorders. A recent study
has reported on the use of DNA microarray technology to
assess the changes in gene expression associated with
obesity and diabetes in lean, obese and diabetic mice. The
expression level of .11 000 transcripts was analysed,
finding that the expression of adipogenic genes was reduced
in obesity and diabetes (Nadler et al. 2000). Oligonucleotide
microarrays have also been used to study the components of
the transcriptional programme specifically affected by
leptin in ob/ob mice. This study found that many adipose
tissue genes were differentially expressed between ob/ob
and lean mice, and also identified a series of gene clusters
that are specifically regulated by leptin and that distinguish
leptin treatment from food restriction (Soukas et al. 2000).
Microarray technology, therefore, is providing insight into
the molecular events implicated in the development of
obesity, diabetes and other nutritionally-related disorders
that would be difficult to obtain using the traditional gene-
by-gene approach.
Oligonucleotide microarray (DNA chip)-based hybridiz-
ation analysis also constitutes a promising new technology
for exploring the genome (Brown & Botstein, 1999). Thus,
Gabrielsson et al. (2000) have performed a partial genome
scale analysis of gene expression in human adipose tissue
using DNA array. This study allowed the identification of
numerous genes not previously reported to be expressed in
adipose tissue, suggesting novel candidate genes involved in
the pathophysiology of obesity (Gabrielsson et al. 2000).
Array technology can also be used for the screening of
possible mutations and sequence variations in genomic
DNA (Hacia, 1999). Microarray technology, therefore,
constitutes a useful tool in clinical diagnosis by detecting
gene expression mutations associated with disease states in
either biopsies or peripheral blood cells (Brugarolas et al.
2001). In this sense, a Gene Chip p53 assay has been used to
detect the accumulation of p53 mutations during carcino-
genesis and the development of gastrointestinal cancers
(Takahashi et al. 2000). With regard to obesity, spontaneous
mutations in five different genes have been found to be
responsible for obesity in mouse models of obesity, i.e. the
obese (ob ), diabetes (db ), the agouti yellow (A y), the fat
and tubby mutations. Mutations in some of these genes have
also been related to the susceptibility to develop obesity in
man (for review, see Bouchard et al. 1999). In addition,
studies published in the last few years have provided
evidence for an association between obesity-related
phenotypes and polymorphisms in uncoupling proteins 2
and 3, peroxisome proliferator-activated receptor g, b2-
-adrenergic receptor, apolipoprotein A4, insulin receptor
substrate I (for review, see Chagnon et al. 2000).
Furthermore, several groups reported additive effects of
polymorphisms on the development of obesity. One
example is the finding that the polymorphism in the
uncoupling protein 1 and b3-adrenergic receptor genes had
an additive action on weight loss (Fogelholm et al. 1998;
Kogure et al. 1998).
DNA hybridization arrays, therefore, represent a huge
opportunity to study the association of a number of different
polymorphisms with the development of obesity. In
addition, the design of cDNA chips that allow the
identification of possible mutations in candidate genes
related to obesity might soon be very useful in clinical
practice. The cDNA chips will help to characterize the
aetiology of obesity and, therefore, a better approach for its
Fig. 1. cDNA microarray schema: polymerase chain reaction (PCR) products represent-
ing specific genes are robotically printed on a glass or plastic matrix. RNA samples from
lean and obese individuals are fluorescently labelled by a single round of reverse tran-
scription, and then competitively hybridized to the same array. Fluorescent scanners are
used for detection and the microarray data are analysed with sophisticated computer
programs.
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treatment. In addition, the early identification of the genetic
predisposition to obesity will enable physicians to choose
the appropriate preventive intervention for each patient,
involving nutritional or exercise programmes. In this sense
it has been shown that the association of some gene
polymorphisms with an obese phenotype depends on the
environment (diet and physical activity). For example, the
Gln27Glu polymorphism of the b2-adrenergic receptor gene
is associated with high body weight and BMI in sedentary
men but not in physically active men (Meirhaeghe et al.
1999).
DNA chips will also be very useful to study the effects of
the type of nutrients in the diet on the expression of obesity-
related genes. A recent study has already used DNA
expression arrays to determine the effect of energy
restriction on the age-related changes in gene expression
(Han et al. 2000). It has been proposed that DNA chips will
soon be used to monitor gene expression in response to a
wide variety of nutritional events (Roberts et al. 2000).
DNA microarray technology is also being used in drug
discovery and development. The opportunity to compare the
expression of thousands of genes between ‘disease’ and
‘normal’ tissues and cells will allow the identification of
multiple potential targets for therapeutic intervention
(Debouck & Goodfellow, 1999). Two recent studies have
used microarrays as a tool for investigating the mechanism
of drug action (Gray et al. 1998; Marton et al. 1998).
Differential gene expression technologies have also been
used for elucidating both drug efficacy and toxicity, as well
as novel candidate genes for pharmacogenetic analyses to
assess individual variability to drug response (Nuwaysir
et al. 1999; Rininger et al. 2000). b3-Adrenergic agonists
have been described as potential anti-diabetic and anti-
obesity drugs, through effects on white adipose tissue.
cDNA microarrays have been used to explore the molecular
mechanisms of this response to b3-adrenergic agonists.
These studies found that the drugs alter the expression of
some adipose tissue genes such as fibroblast growth factor
and tumour necrosis factor a-induced protein, which may
modulate the b3-adrenergic inhibition of food intake (Ye
et al. 2000). The cDNA chips, therefore, can be useful tools
for the discovery of anti-obesity drugs, as well as for the
identification of their mechanisms of action.
In summary, cDNA array technology, despite some
limitations such as the high cost, provides a powerful
opportunity for obesity researchers and nutritionists. This
technology constitutes the appropriate tool for studying
those combinations of genes and mutations that are involved
in the development of obesity in man, as well as for
establishing the participation of environmental factors on
the onset of obesity in individuals with a specific genetic
background.
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